FDA speeds up review of Droxidopa
The drug is marketed in Japan to treat low blood pressure.
The Food and Drug Administration has given fast-track designation to Droxidopa, which is marketed in Japan to treat low blood pressure. Such a designation is reserved for drugs that treat serious conditions for which there is an unmet need. The maker of the drug, Chelsea Therapeutics International, says it plans to seek marketing approval for Droxidopa after completing clinical trials this year.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, clickhere.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.
